The involvement of TNF-α in cognitive dysfunction associated with major depressive disorder: An opportunity for domain specific treatments

Current Neuropharmacology

Volumn 13, Issue 5, 2015, Pages 558-576

  Bortolato, Beatrice ^a   Carvalho, Andre F ^b   Soczynska, Joanna K ^c,d   Perini, Giulia I ^e   McIntyre, Roger S ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Department of Mental Health   (Italy)

Author keywords

Antidepressant; Cytokines; Depression; Inflammation; TNF ; TNF antagonists

Indexed keywords

ADALIMUMAB; CASPASE 3; CASPASE 8; CERTOLIZUMAB PEGOL; CXCL13 CHEMOKINE; ETANERCEPT; FLUOXETINE; GAMMA INTERFERON; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAROXETINE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SERTRALINE; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; ASSESSMENT OF HUMANS; CELL PROLIFERATION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LIPID PEROXIDATION; LONG TERM DEPRESSION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ANTAGONISTS AND INHIBITORS; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; MEDLINE; METABOLISM; STATISTICS AND NUMERICAL DATA;

ANIMALS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MEDLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84946713014     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666150630171433     Document Type: Article

References (150)

1. McIntyre, R.S.; Cha, D.S.; Soczynska, J.K. Cognitive deficits andfunctional outcomes in major depressive disorder: determinants,substrates, and treatment interventions. Depress. Anxiety, 2013,30(6), 515-527. http://dx.doi.org/10.1002/da.22063
2. Dowlati, Y.; Herrmann, N.; Swardfager, W. A meta-analysis ofcytokines in major depression. Biol. Psychiatry, 2010, 67(5), 446-457. http://dx.doi.org/10.1016/j.biopsych.2009.09.033
3. Stuart, M.J.; Baune, B.T. Chemokines and chemokine receptors inmood disorders, schizophrenia, and cognitive impairment: Asystematic review of biomarker studies. Neurosci. Biobehav. Rev., 2014, 42C, 93-115. http://dx.doi.org/10.1016/j.neubiorev.2014.02.001
4. Moylan, S.; Maes, M.; Wray, N.R.; Berk, M. The neuroprogressivenature of major depressive disorder: pathways to disease evolutionand resistance, and therapeutic implications. Mol. Psychiatry, 2013,18(5), 595-606. http://dx.doi.org/10.1038/mp.2012.33
5. Kreisel, T.; Frank, M.G.; Licht, T. Dynamic microglial alterationsunderlie stress-induced depressive-like behavior and suppressedneurogenesis. Mol. Psychiatry, 2014, 19(6), 699-709. http://dx.doi.org/10.1038/mp.2013.155
6. Anderson, G.; Berk, M.; Dean, O.; Moylan, S.; Maes, M. Role ofimmune-inflammatory and oxidative and nitrosative stresspathways in the etiology of depression: therapeutic implications. CNS Drugs, 2014, 28(1), 1-10. http://dx.doi.org/10.1007/s40263-013-0119-1
7. Carvalho, A.F.; Berk, M.; Hyphantis, T.N.; McIntyre, R.S. Theintegrative management of treatment-resistant depression: Acomprehensive review and perspectives. Psychother. Psychosom.,2014, 83(2), 70-88. http://dx.doi.org/10.1159/000357500
8. Hasselbalch, B.J.; Knorr, U.; Kessing, L.V. Cognitive impairmentin the remitted state of unipolar depressive disorder: a systematicreview. J. Affect. Disord., 2011, 134(1-3), 20-31. http://dx.doi.org/10.1016/j.jad.2010.11.011
9. Maes, M.; Leonard, B.E.; Myint, A.M.; Kubera, M.; Verkerk, R. The new '5-HT' hypothesis of depression: cell-mediated immuneactivation induces indoleamine 2,3-dioxygenase, which leads tolower plasma tryptophan and an increased synthesis of detrimentaltryptophan catabolites (TRYCATs), both of which contribute to theonset of depression. Prog. Neuro-Pychopharmacol. Biol. Psychiatry,2011, 35(3), 702-721. http://dx.doi.org/10.1016/j.pnpbp.2010.12.017
10. Leonard, B.E. Impact of inflammation on neurotransmitter changesin major depression: an insight into the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 48, 261-267. http://dx.doi.org/10.1016/j.pnpbp.2013.10.018
11. Maes, M.; Ringel, K.; Kubera, M.; Berk, M.; Rybakowski, J. Increased autoimmune activity against 5-HT: a key component ofdepression that is associated with inflammation and activation ofcell-mediated immunity, and with severity and staging ofdepression. J. Affect. Disord., 2012, 136(3), 386-392. http://dx.doi.org/10.1016/j.jad.2011.11.016
12. Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of celecoxib add-on treatment onsymptoms and serum IL-6 concentrations in patients with majordepressive disorder: randomized double-blind placebo-controlledstudy. J. Affect. Disord., 2012, 141(2-3), 308-314. http://dx.doi.org/10.1016/j.jad.2012.03.033
13. Galecki, P.; Szemraj, J.; Bienkiewicz, M.; Zboralski, K.; Galecka, E. Oxidative stress parameters after combined fluoxetine andacetylsalicylic acid therapy in depressive patients. Hum. Psychopharmacol.,2009, 24(4), 277-286. http://dx.doi.org/10.1002/hup.1014
14. Soczynska, J.K.; Mansur, R.B.; Brietzke, E. Novel therapeutictargets in depression: minocycline as a candidate treatment. Behav.Brain Res., 2012, 235(2), 302-317. http://dx.doi.org/10.1016/j.bbr.2012.07.026
15. Miyaoka, T.; Wake, R.; Furuya, M. Minocycline as adjunctivetherapy for patients with unipolar psychotic depression: an openlabelstudy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012,37(2), 222-226. http://dx.doi.org/10.1016/j.pnpbp.2012.02.002
16. Naismith, S.L.; Longley, W.A.; Scott, E.M.; Hickie, I.B. Disabilityin major depression related to self-rated and objectively-measuredcognitive deficits: a preliminary study. BMC Psychiatry, 2007, 7,32. http://dx.doi.org/10.1186/1471-244X-7-32
17. Eisenberger, N.I.; Berkman, E.T.; Inagaki, T.K.; Rameson, L.T.; Mashal, N.M.; Irwin, M.R. Inflammation-induced anhedonia:endotoxin reduces ventral striatum responses to reward. Biol.Psychiatry, 2010, 68(8), 748-754. http://dx.doi.org/10.1016/j.biopsych.2010.06.010
18. Kheirbek, M.A.; Hen, R. Dorsal vs ventral hippocampal neurogenesis:implications for cognition and mood. Neuropsychopharmacology,2011, 36(1), 373-374. http://dx.doi.org/10.1038/npp.2010.148
19. Stahl, S.M. Enhancing outcomes from major depression: usingantidepressant combination therapies with multifunctionalpharmacologic mechanisms from the initiation of treatment. CNSSpectr., 2010, 15 (2), 79-94.
20. Frodl, T.; Amico, F. Is there an association between peripheralimmune markers and structural/functional neuroimaging findings? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 48, 295-303. http://dx.doi.org/10.1016/j.pnpbp.2012.12.013
21. Clark, I.A.; Alleva, L.M.; Vissel, B. The roles of TNF in braindysfunction and disease. Pharmacol. Ther., 2010, 128 (3), 519-48. http://dx.doi.org/10.1016/j.pharmthera.2010.08.007
22. Kaster, M.P.; Gadotti, V.M.; Calixto, J.B.; Santos, A.R.; Rodrigues, A.L. Depressive-like behavior induced by tumornecrosis factor-alpha in mice. Neuropharmacology, 2012, 62 (1),419-426. http://dx.doi.org/10.1016/j.neuropharm.2011.08.018
23. Souza, L.C.; Filho, C.B.; Fabbro, L.D.; de Gomes, M.G.; Goes, A.T.; Jesse, C.R. Depressive-like behaviour induced by anintracerebroventricular injection of streptozotocin in mice: Theprotective effect of fluoxetine, antitumour necrosis factor-alpha andthalidomide therapies. Behav. Pharmacol., 2013, 24(2), 79-86. http://dx.doi.org/10.1097/FBP.0b013e32835efc2f
24. Belarbi, K.; Jopson, T.; Tweedie, D. TNF-alpha protein synthesisinhibitor restores neuronal function and reverses cognitive deficitsinduced by chronic neuroinflammation. J. Neuroinflamm., 2012, 9,23. http://dx.doi.org/10.1186/1742-2094-9-23
25. Eller, T.; Vasar, V.; Shlik, J.; Maron, E. Pro-inflammatory cytokinesand treatment response to escitalopram in major depressivedisorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008,32(2), 445-450. http://dx.doi.org/10.1016/j.pnpbp.2007.09.015
26. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J. A randomizedcontrolled trial of the tumor necrosis factor antagonist infliximabfor treatment-resistant depression: the role of baselineinflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41. http://dx.doi.org/10.1001/2013.jamapsychiatry.4
27. Tracey, D.; Klareskog, L.; Sasso, E.H.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: acomprehensive review. Pharmacol. Ther., 2008, 117(2), 244-279. http://dx.doi.org/10.1016/j.pharmthera.2007.10.001
28. Wong, M.; Ziring, D.; Korin, Y. TNFalpha blockade in humandiseases: mechanisms and future directions. Clin. Immunol., 2008,126(2), 121-136. http://dx.doi.org/10.1016/j.clim.2007.08.013
29. Zhou, M.; Wang, C.M.; Yang, W.L.; Wang, P. Microglial CD14activated by iNOS contributes to neuroinflammation in cerebralischemia. Brain Res., 2013, 1506, 105-14. http://dx.doi.org/10.1016/j.brainres.2013.02.010
30. Sato, T.A.; Keelan, J.A.; Mitchell, M.D. Critical paracrine interactionsbetween TNF-alpha and IL-10 regulate lipopolysaccharidestimulatedhuman choriodecidual cytokine and prostaglandin E2production. J. Immunol., 2003, 170(1), 158-66. http://dx.doi.org/10.4049/jimmunol.170.1.158
31. Kollias, G. TNF pathophysiology in murine models of chronicinflammation and autoimmunity. Semin. Arthritis Rheum., 2005, 34(Suppl1), 3-6. http://dx.doi.org/10.1016/j.semarthrit.2005.01.002
32. Gommerman, J.L.; Browning, J.L. Lymphotoxin/light, lymphoidmicroenvironments and autoimmune disease. Nat. Rev. Immunol.,2003, 3(8), 642-655. http://dx.doi.org/10.1038/nri1151
33. Maes, M.; Yirmyia, R.; Noraberg, J. The inflammatory & neurodegenerative (I& ND) hypothesis of depression: leads forfuture research and new drug developments in depression. Metab.Brain Dis., 2009, 24(1), 27-53. http://dx.doi.org/10.1007/s11011-008-9118-1
34. Bernardino, L.; Agasse, F.; Silva, B.; Ferreira, R.; Grade, S.; Malva, J.O. Tumor necrosis factor-alpha modulates survival, proliferation,and neuronal differentiation in neonatal subventricular zone cellcultures. Stem Cells, 2008, 26(9), 2361-2371. http://dx.doi.org/10.1634/stemcells.2007-0914
35. Qin, L.; Wu, X.; Block, M.L. Systemic LPS causes chronicneuroinflammation and progressive neurodegeneration. Glia, 2007,55(5), 453-462. http://dx.doi.org/10.1002/glia.20467
36. McCoy, M.K.; Tansey, M.G. TNF signaling inhibition in the CNS:implications for normal brain function and neurodegenerativedisease. J. Neuroinflamm., 2008, 5, 45. http://dx.doi.org/10.1186/1742-2094-5-45
37. Kerfoot, S.M.; D'Mello, C.; Nguyen, H. TNF-alpha-secretingmonocytes are recruited into the brain of cholestatic mice. Hepatology, 2006, 43(1), 154-162. http://dx.doi.org/10.1002/hep.21003
38. Najjar, S.; Pearlman, D.M.; Alper, K.; Najjar, A.; Devinsky, O. Neuroinflammation and psychiatric illness. J. Neuroinflamm.,2013, 10, 43. http://dx.doi.org/10.1186/1742-2094-10-43
39. Muller, N.; Schwarz, M.J. The immune-mediated alteration ofserotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry, 2007, 12 (11), 988-1000. http://dx.doi.org/10.1038/sj.mp.4002006
40. Edgar, N.; Sibille, E. A putative functional role foroligodendrocytes in mood regulation. Transl. Psychiatry, 2012, 2,e109. http://dx.doi.org/10.1038/tp.2012.34
41. Blaylock, R.L.; Maroon, J. Immunoexcitotoxicity as a centralmechanism in chronic traumatic encephalopathy-A unifying hypothesis. Surg. Neurol. Int., 2011, 2, 107. http://dx.doi.org/10.4103/2152-7806.83391
42. Stellwagen, D.; Beattie, E.C.; Seo, J.Y.; Malenka, R.C. Differentialregulation of AMPA receptor and GABA receptor trafficking bytumor necrosis factor-alpha. J. Neurosci., 2005, 25 (12), 3219-3228. http://dx.doi.org/10.1523/JNEUROSCI.4486-04.2005
43. Fan, L.W.; Tien, L.T.; Zheng, B. Dopaminergic neuronal injury in theadult rat brain following neonatal exposure to lipopolysaccharideand the silent neurotoxicity. Brain Behav. Immun., 2011, 25(2),286-297. http://dx.doi.org/10.1016/j.bbi.2010.09.020
44. Beattie, E.C.; Stellwagen, D.; Morishita, W. Control of synapticstrength by glial TNFalpha. Science, 2002, 295 (5563), 2282-2285. http://dx.doi.org/10.1126/science.1067859
45. Butler, M.P.; O'Connor, J.J.; Moynagh, P.N. Dissection of tumornecrosisfactor-alpha inhibition of long-term potentiation (LTP)reveals a p38 mitogen-activated protein kinase-dependent mechanismwhich maps to early-but not late-phase LTP. Neuroscience, 2004,124 (2), 319-326. http://dx.doi.org/10.1016/j.neuroscience.2003.11.040
46. Feleder, C.; Tseng, K.Y.; Calhoon, G.G.; O'Donnell, P. Neonatalintrahippocampal immune challenge alters dopamine modulation ofprefrontal cortical interneurons in adult rats. Biol. Psychiatry, 2010,67(4), 386-392. http://dx.doi.org/10.1016/j.biopsych.2009.09.028
47. Babri, S.; Doosti, M.H.; Salari, A.A. Tumor necrosis factor-alphaduring neonatal brain development affects anxiety- and depressionrelatedbehaviors in adult male and female mice. Behav. Brain Res.,2014, 261, 305-314. http://dx.doi.org/10.1016/j.bbr.2013.12.037
48. MacEwan, D.J. TNF receptor subtype signalling: differences andcellular consequences. Cell. Signal., 2002, 14(6), 477-492. http://dx.doi.org/10.1016/S0898-6568(01)00262-5
49. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J.; Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995, 270(5240), 1326-1331. http://dx.doi.org/10.1126/science.270.5240.1326
50. Imayoshi, I.; Sakamoto, M.; Ohtsuka, T. Roles of continuousneurogenesis in the structural and functional integrity of the adultforebrain. Nat. Neurosci., 2008, 11(10), 1153-1161. http://dx.doi.org/10.1038/nn.2185
51. Marchetti, L.; Klein, M.; Schlett, K.; Pfizenmaier, K.; Eisel, U.L. Tumor necrosis factor (TNF)-mediated neuroprotection againstglutamate-induced excitotoxicity is enhanced by N-methyl-Daspartatereceptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa Bpathway. J. Biol. Chem., 2004, 279 (31), 32869-32881. http://dx.doi.org/10.1074/jbc.M311766200
52. Sama, D.M.; Mohmmad, A. H.; Furman, J.L. Inhibition of solubletumor necrosis factor ameliorates synaptic alterations and Ca2+dysregulation in aged rats. PloS One, 2012, 7(5), e38170. http://dx.doi.org/10.1371/journal.pone.0038170
53. Dunn, A.J.; Swiergiel, A.H.; de Beaurepaire, R. Cytokines asmediators of depression: what can we learn from animal studies?Neurosci. Biobehav. Rev., 2005, 29(45), 891-909. http://dx.doi.org/10.1016/j.neubiorev.2005.03.023
54. You, Z.; Luo, C.; Zhang, W. Pro- and anti-inflammatory cytokinesexpression in rat's brain and spleen exposed to chronic mild stress:involvement in depression. Behav. Brain Res., 2011, 225(1), 135-141. http://dx.doi.org/10.1016/j.bbr.2011.07.006
55. van Heesch, F.; Prins, J.; Korte-Bouws, G.A. Systemic tumornecrosis factor-alpha decreases brain stimulation reward andincreases metabolites of serotonin and dopamine in the nucleusaccumbens of mice. Behav. Brain Res., 2013, 253, 191-195. http://dx.doi.org/10.1016/j.bbr.2013.07.038
56. Zhu, C.B.; Blakely, R.D.; Hewlett, W.A. The proinflammatorycytokines interleukin-1beta and tumor necrosis factor-alphaactivate serotonin transporters. Neuropsychopharmacology, 2006,31(10), 2121-2131. http://dx.doi.org/10.1038/sj.npp.1301029
57. Simen, B.B.; Duman, C.H.; Simen, A.A.; Duman, R.S. TNFalphasignaling in depression and anxiety: behavioral consequences ofindividual receptor targeting. Biol. Psychiatry, 2006, 59(9), 775-785. http://dx.doi.org/10.1016/j.biopsych.2005.10.013
58. Yamada, K.; Iida, R.; Miyamoto, Y. Neurobehavioral alterations inmice with a targeted deletion of the tumor necrosis factor-alpha gene:implications for emotional behavior. J. Neuroimmunol., 2000,111(12), 131-138. http://dx.doi.org/10.1016/S0165-5728(00)00375-1
59. McAfoose, J.; Baune, B.T. Evidence for a cytokine model ofcognitive function. Neurosci. Biobehav. Rev., 2009, 33(3), 355-366. http://dx.doi.org/10.1016/j.neubiorev.2008.10.005
60. Takei, Y.; Laskey, R. Interpreting crosstalk between TNF-alphaand NGF: potential implications for disease. Trends Mol. Med.,2008, 14(9), 381-388. http://dx.doi.org/10.1016/j.molmed.2008.07.002
61. Golan, H.; Levav, T.; Mendelsohn, A.; Huleihel, M. Involvementof tumor necrosis factor alpha in hippocampal development andfunction. Cereb. Cortex, 2004, 14(1), 97-105. http://dx.doi.org/10.1093/cercor/bhg108
62. Baune, B.T.; Wiede, F.; Braun, A.; Golledge, J.; Arolt, V.; Koerner, H. Cognitive dysfunction in mice deficient for TNF- andits receptors. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2008,147B(7), 1056-1064. http://dx.doi.org/10.1002/ajmg.b.30712
63. He, P.; Cheng, X.; Staufenbiel, M.; Li, R.; Shen, Y. Long-termtreatment of thalidomide ameliorates amyloid-like pathologythrough inhibition of beta-secretase in a mouse model of Alzheimer'sdisease. PloS One, 2013, 8(2), e55091. http://dx.doi.org/10.1371/journal.pone.0055091
64. Kubera, M.; Obuchowicz, E.; Goehler, L.; Brzeszcz, J.; Maes, M. Inanimal models, psychosocial stress-induced (neuro) inflammation,apoptosis and reduced neurogenesis are associated to the onset ofdepression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011,35(3), 744-759. http://dx.doi.org/10.1016/j.pnpbp.2010.08.026
65. Brustolim, D.; Ribeiro-dos-Santos, R.; Kast, R.E.; Altschuler, E. L.; Soares, M.B. A new chapter opens in anti-inflammatory treatments:the antidepressant bupropion lowers production of tumor necrosisfactor-alpha and interferon-gamma in mice. Int. Immunopharmacol.,2006, 6(6), 903-907. http://dx.doi.org/10.1016/j.intimp.2005.12.007
66. Song, C.; Killeen, A.A.; Leonard, B.E. Catalase, superoxidedismutase and glutathione peroxidase activity in neutrophils ofsham-operated and olfactory-bulbectomised rats following chronictreatment with desipramine and lithium chloride. Neuropsychobiology,1994, 30 (1), 24-8. http://dx.doi.org/10.1159/000119131
67. Grippo, A.J.; Beltz, T.G.; Weiss, R.M.; Johnson, A.K. The effectsof chronic fluoxetine treatment on chronic mild stress-inducedcardiovascular changes and anhedonia. Biol. Psychiatry, 2006,59(4), 309-316. http://dx.doi.org/10.1016/j.biopsych.2005.07.010
68. Ohgi, Y.; Futamura, T.; Kikuchi, T.; Hashimoto, K. Effects ofantidepressants on alternations in serum cytokines and depressivelikebehavior in mice after lipopolysaccharide administration.Pharmacol. Biochem. Behav., 2013, 103(4), 853-859. http://dx.doi.org/10.1016/j.pbb.2012.12.003
69. Tynan, R.J.; Weidenhofer, J.; Hinwood, M.; Cairns, M.J.; Day, T.A.; Walker, F.R. A comparative examination of the antiinflammatoryeffects of SSRI and SNRI antidepressants on LPSstimulated microglia. Brain Behav. Immun., 2012, 26(3), 469-479. http://dx.doi.org/10.1016/j.bbi.2011.12.011
70. Liu, D.; Wang, Z.; Liu, S.; Wang, F.; Zhao, S.; Hao, A. Antiinflammatoryeffects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology, 2011, 61(4), 592-599. http://dx.doi.org/10.1016/j.neuropharm.2011.04.033
71. Dhami, K.S.; Churchward, M.A.; Baker, G.B.; Todd, K.G. Fluoxetine and citalopram decrease microglial release of glutamateand D-serine to promote cortical neuronal viability followingischemic insult. Mol. Cell. Neurosci., 2013, 56, 365-374. http://dx.doi.org/10.1016/j.mcn.2013.07.006
72. Takeuchi, H.; Jin, S.; Wang, J. Tumor necrosis factor-alpha inducesneurotoxicity via glutamate release from hemichannels of activatedmicroglia in an autocrine manner. J. Biol. Chem., 2006, 281 (30),21362-8. http://dx.doi.org/10.1074/jbc.M600504200
73. Huang, Y.Y.; Peng, C.H.; Yang, Y.P. Desipramine activated Bcl-2expression and inhibited lipopolysaccharide-induced apoptosis inhippocampus-derived adult neural stem cells. J. Pharmacol. Sci.,2007, 104(1), 61-72. http://dx.doi.org/10.1254/jphs.FP0061255
74. Krabbe, G.; Matyash, V.; Pannasch, U.; Mamer, L.; Boddeke, H.W.; Kettenmann, H. Activation of serotonin receptors promotesmicroglial injury-induced motility but attenuates phagocyticactivity. Brain Behav. Immun., 2012, 26(3), 419-428. http://dx.doi.org/10.1016/j.bbi.2011.12.002
75. Allaman, I.; Fiumelli, H.; Magistretti, P.J.; Martin, J.L. Fluoxetineregulates the expression of neurotrophic/growth factors and glucosemetabolism in astrocytes. Psychopharmacology, 2011, 216(1), 75-84. http://dx.doi.org/10.1007/s00213-011-2190-y
76. Czeh, B.; Di Benedetto, B. Antidepressants act directly on astrocytes:evidences and functional consequences. Eur. Neuropsychopharmacol.,2013, 23 (3), 171-185. http://dx.doi.org/10.1016/j.euroneuro.2012.04.017
77. Schafer, D.P.; Lehrman, E.K.; Kautzman, A.G. Microglia sculptpostnatal neural circuits in an activity and complement-dependent manner. Neuron, 2012, 74(4), 691-705. http://dx.doi.org/10.1016/j.neuron.2012.03.026
78. Della, G. N.; Hannestad, J. A critical review of human endotoxinadministration as an experimental paradigm of depression. Neurosci. Biobehav. Rev., 2010, 34 (1), 130-43. http://dx.doi.org/10.1016/j.neubiorev.2009.07.014
79. Khandaker, G.M.; Zimbron, J.; Lewis, G.; Jones, P.B. Prenatalmaternal infection, neurodevelopment and adult schizophrenia: asystematic review of population-based studies. Psychol. Med., 2013,43(2), 239-257. http://dx.doi.org/10.1017/S0033291712000736
80. Chapman, D.P.; Perry, G.S.; Strine, T.W. The vital link betweenchronic disease and depressive disorders. Prev. Chronic Dis., 2005,2(1), A14.
81. Dowlatshahi, E.A.; Wakkee, M.; Arends, L.R.; Nijsten, T. Theprevalence and odds of depressive symptoms and clinical depressionin psoriasis patients: a systematic review and meta-analysis. J. Invest. Dermatol., 2014, 134(6), 1542-1551. http://dx.doi.org/10.1038/jid.2013.508
82. El-Tantawy, A.M.; El-Sayed, A.E.; Kora, B.A.; Amin, R.T. Psychiatric morbidity associated with some cytokines (IL-1beta,IL-12, IL-18 and TNF-alpha) among rheumatoid arthritis patients. Egypt J. Immunol., 2008, 15(1), 1-11.
83. Loftis, J.M.; Huckans, M.; Ruimy, S.; Hinrichs, D.J.; Hauser, P. Depressive symptoms in patients with chronic hepatitis C arecorrelated with elevated plasma levels of interleukin-1beta andtumor necrosis factor-alpha. Neurosci. Lett., 2008, 430(3), 264-268. http://dx.doi.org/10.1016/j.neulet.2007.11.001
84. Krueger, C.; Hawkins, K.; Wong, S.; Enns, M.W.; Minuk, G.; Rempel, J.D. Persistent pro-inflammatory cytokines following theinitiation of pegylated IFN therapy in hepatitis C infection isassociated with treatment-induced depression. J. Viral Hepat.,2011, 18(7), e284-291. http://dx.doi.org/10.1111/j.1365-2893.2010.01408.x
85. Grassi-Oliveira, R.; Brietzke, E.; Pezzi, J.C.; Lopes, R.P.; Teixeira, A. L.; Bauer, M. E. Increased soluble tumor necrosis factor-alphareceptors in patients with major depressive disorder. PsychiatryClin. Neurosci., 2009, 63(2), 202-208. http://dx.doi.org/10.1111/j.1440-1819.2008.01918.x
86. Himmerich, H.; Fulda, S.; Linseisen, J. Depression, comorbiditiesand the TNF-alpha system. Eur. Psychiatry, 2008, 23(6), 421-429. http://dx.doi.org/10.1016/j.eurpsy.2008.03.013
87. Miller, A.H.; Haroon, E.; Raison, C.L.; Felger, J.C. Cytokinetargets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety, 2013, 30(4), 297-306. http://dx.doi.org/10.1002/da.22084
88. Yoon, H.K.; Kim, Y.K.; Lee, H.J.; Kwon, D.Y.; Kim, L. Role ofcytokines in atypical depression. Nord. J. Psychiatry, 2012, 66(3),183-188. http://dx.doi.org/10.3109/08039488.2011.611894
89. Karlovic, D.; Serretti, A.; Vrkic, N.; Martinac, M.; Marcinko, D., Serum concentrations of CRP, IL-6, TNF-alpha and cortisol inmajor depressive disorder with melancholic or atypical features. Psychiatry Res., 2012, 198(1), 74-80. http://dx.doi.org/10.1016/j.psychres.2011.12.007
90. Lamers, F.; Vogelzangs, N.; Merikangas, K.R.; de Jonge, P.; Beekman, A.T.; Penninx, B.W. Evidence for a differential role ofHPA-axis function, inflammation and metabolic syndrome inmelancholic versus atypical depression. Mol. Psychiatry, 2013,18(6), 692-699. http://dx.doi.org/10.1038/mp.2012.144
91. Bufalino, C.; Hepgul, N.; Aguglia, E.; Pariante, C.M. The role ofimmune genes in the association between depression andinflammation: a review of recent clinical studies. Brain Behav.Immun., 2013, 31, 31-47. http://dx.doi.org/10.1016/j.bbi.2012.04.009
92. Jun, T.Y.; Pae, C.U.; Chae, J.H. TNFB polymorphism may beassociated with schizophrenia in the Korean population. Schizophr.Res., 2003, 61(1), 39-45. http://dx.doi.org/10.1016/S0920-9964(02)00303-1
93. Cerri, A.P.; Arosio, B.; Viazzoli, C.; Confalonieri, R.; Vergani, C.; Annoni, G. The -308 (G/A) single nucleotide polymorphism in theTNF-alpha gene and the risk of major depression in the elderly. Int. J.Ger. Psychiatry, 2010, 25(3), 219-223. http://dx.doi.org/10.1002/gps.2323
94. Kim, Y.K.; Hong, J.P.; Hwang, J.A. TNF-alpha -308G>Apolymorphism is associated with suicide attempts in majordepressive disorder. J. Affect. Disord., 2013, 150(2), 668-672. http://dx.doi.org/10.1016/j.jad.2013.03.019
95. Dean, B.; Tawadros, N.; Scarr, E.; Gibbons, A. S. Regionallyspecificchanges in levels of tumour necrosis factor in thedorsolateral prefrontal cortex obtained postmortem from subjectswith major depressive disorder. J. Affect. Disord., 2010, 120(1-3),245-8. http://dx.doi.org/10.1016/j.jad.2009.04.027
96. Dean, B.; Gibbons, A.S.; Tawadros, N.; Brooks, L.; Everall, I.P.; Scarr, E. Different changes in cortical tumor necrosis factor-alpharelatedpathways in schizophrenia and mood disorders. Mol.Psychiatry 2013, 18(7), 767-773. http://dx.doi.org/10.1038/mp.2012.95
97. Pandey, G.N.; Rizavi, H.S.; Ren, X. Proinflammatory cytokines inthe prefrontal cortex of teenage suicide victims. J. Psychiatry Res.,2012, 46(1), 57-63. http://dx.doi.org/10.1016/j.jpsychires.2011.08.006
98. Serafini, G.; Pompili, M.; Elena Seretti, M. The role ofinflammatory cytokines in suicidal behavior: a systematic review. Eur. Neuropsychopharmacol., 2013, 23(12), 1672-1686. http://dx.doi.org/10.1016/j.euroneuro.2013.06.002
99. O'Donovan, A.; Rush, G.; Hoatam, G. Suicidal ideation isassociated with elevated inflammation in patients with majordepressive disorder. Depress Anxiety, 2013, 30(4), 307-314. http://dx.doi.org/10.1002/da.22087
100. Lindqvist, D.; Janelidze, S.; Hagell, P.; Erhardt, S.; Samuelsson, M.; Minthon, L.; Hansson, O.; Björkqvist, M.; Träskman-Bendz, L.; Brundin, L. Interleukin-6 is elevated in the cerebrospinal fluidof suicide attempters and related to symptom severity. Biol.Psychiatry 2009, 66(3), 287-292. http://dx.doi.org/10.1016/j.biopsych.2009.01.030
101. Kim, Y.K.; Lee, S.W.; Kim, S.H. Differences in cytokines betweennon-suicidal patients and suicidal patients in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(2), 356-361. http://dx.doi.org/10.1016/j.pnpbp.2007.08.041
102. Danese, A.; Pariante, C.M.; Caspi, A.; Taylor, A.; Poulton, R. Childhood maltreatment predicts adult inflammation in a lifecoursestudy. Proc. Natl. Acad. Sci. U S A, 2007, 104(4), 1319-1324. http://dx.doi.org/10.1073/pnas.0610362104
103. Hartwell, K.J.; Moran-Santa Maria, M.M.; Twal, W.O. Associationof elevated cytokines with childhood adversity in a sample ofhealthy adults. J. Psychiatr. Res., 2013, 47(5), 604-610. http://dx.doi.org/10.1016/j.jpsychires.2013.01.008
104. Blackmore, E.R.; Moynihan, J.A.; Rubinow, D.R.; Pressman, E.K.; Gilchrist, M.; O'Connor, T.G. Psychiatric symptoms andproinflammatory cytokines in pregnancy. Psychosom. Med., 2011,73(8), 656-663. http://dx.doi.org/10.1097/PSY.0b013e31822fc277
105. Hannestad, J.; DellaGioia, N.; Bloch, M. The effect of antidepressantmedication treatment on serum levels of inflammatory cytokines: Ameta-analysis. Neuropsychopharmacology, 2011, 36(12), 2452-2459. http://dx.doi.org/10.1038/npp.2011.132
106. Lanquillon, S.; Krieg, J.C.; Bening-Abu-Shach, U.; Vedder, H. Cytokine production and treatment response in major depressivedisorder. Neuropsychopharmacology, 2000, 22(4), 370-379. http://dx.doi.org/10.1016/S0893-133X(99)00134-7
107. Hestad, K.A.; Tonseth, S.; Stoen, C.D.; Ueland, T.; Aukrust, P. Raised plasma levels of tumor necrosis factor alpha in patients withdepression: normalization during electroconvulsive therapy. J.ECT, 2003, 19(4), 183-188. http://dx.doi.org/10.1097/00124509-200312000-00002
108. Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increasedserum tumor necrosis factor-alpha levels and treatment response inmajor depressive disorder. Psychopharmacology (Berl), 2003,170(4), 429-433. http://dx.doi.org/10.1007/s00213-003-1566-z
109. Li, Z.; Qi, D.; Chen, J. Venlafaxine inhibits the upregulation ofplasma tumor necrosis factor-alpha (TNF-alpha) in the Chinesepatients with major depressive disorder: a prospective longitudinalstudy. Psychoneuroendocrinology, 2013, 38(1), 107-114. http://dx.doi.org/10.1016/j.psyneuen.2012.05.005
110. Kast, R.E. Anti- and pro-inflammatory considerations inantidepressant use during medical illness: bupropion lowers andmirtazapine increases circulating tumor necrosis factor-alpha levels. Gen. Hosp. Psychiatry, 2003, 25(6), 495-496. http://dx.doi.org/10.1055/s-2002-36390
111. Kraus, T.; Haack, M.; Schuld, A.; Hinze-Selch, D.; Koethe, D.; Pollmacher, T. Body weight, the tumor necrosis factor system, andleptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 2002, 35(6), 220-225. http://dx.doi.org/10.1055/s-2002-36390
112. O'Brien, S.M.; Scully, P.; Fitzgerald, P.; Scott, L.V.; Dinan, T.G. Plasma cytokine profiles in depressed patients who fail to respondto selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res.,2007, 41(34), 326-331. http://dx.doi.org/10.1016/j.jpsychires.2006.05.013
113. Taylor, P.C. Pharmacology of TNF blockade in rheumatoidarthritis and other chronic inflammatory diseases. Curr. Opin.Pharmacol., 2010, 10(3), 308-315. http://dx.doi.org/10.1016/j.coph.2010.01.005
114. Bayramgurler, D.; Karson, A.; Ozer, C.; Utkan, T. Effects of longtermetanercept treatment on anxiety- and depression-likeneurobehaviors in rats. Physiol. Behav., 2013, 119, 145-148. http://dx.doi.org/10.1016/j.physbeh.2013.06.010
115. Krugel, U.; Fischer, J.; Radicke, S.; Sack, U.; Himmerich, H. Antidepressant effects of TNF-alpha blockade in an animal modelof depression. J. Psychiatr. Res., 2013, 47(5), 611-616. http://dx.doi.org/10.1016/j.jpsychires.2013.01.007
116. Karson, A.; Demirtas, T.; Bayramgurler, D.; Balci, F.; Utkan, T. Chronic administration of infliximab (TNF-alpha inhibitor)decreases depression and anxiety-like behaviour in rat model ofchronic mild stress. Basic Clin. Pharmacol. Toxicol., 2013, 112(5),335-340. http://dx.doi.org/10.1111/bcpt.12037
117. Grippo, A.J.; Francis, J.; Weiss, R.M.; Felder, R.B.; Johnson, A.K. Cytokine mediation of experimental heart failure-inducedanhedonia. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003,284(3), R666-673. http://dx.doi.org/10.1152/ajpregu.00430.2002
118. O'Connor, J.C.; Andre, C.; Wang, Y. Interferon-gamma and tumornecrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in micein response to bacillus Calmette-Guerin. J. Neurosci., 2009, 29(13),4200-4209. http://dx.doi.org/10.1523/JNEUROSCI.5032-08.2009
119. Ertenli, I.; Ozer, S.; Kiraz, S. Infliximab, a TNF-alpha antagonisttreatment in patients with ankylosing spondylitis: The impact ondepression, anxiety and quality of life level. Rheumatol. Int., 2012,32(2), 323-330. http://dx.doi.org/10.1007/s00296-010-1616-x
120. Guloksuz, S.; Wichers, M.; Kenis, G. Depressive symptoms inCrohn's disease: relationship with immune activation and tryptophanavailability. PloS One, 2013, 8(3), e60435. http://dx.doi.org/10.1371/journal.pone.0060435
121. Persoons, P.; Vermeire, S.; Demyttenaere, K. The impact of majordepressive disorder on the short- and long-term outcome of Crohn'sdisease treatment with infliximab. Aliment. Pharmacol. Ther.,2005, 22(2), 101-110. http://dx.doi.org/10.1111/j.1365-2036.2005.02535.x
122. Minderhoud, I.M.; Samsom, M.; Oldenburg, B. Crohn's disease,fatigue, and infliximab: is there a role for cytokines in thepathogenesis of fatigue? World J. Gastroenterol., 2007, 13(14),2089-2093.
123. Bassukas, I.D.; Hyphantis, T.; Gamvroulia, C.; Gaitanis, G.; Mavreas, V. Infliximab for patients with plaque psoriasis andsevere psychiatric comorbidity. J. Eur. Acad. Dermatol. Venereol.,2008, 22(2), 257-258.
124. Yip, L.; Harrison, S.; Foley, P. Infliximab rescue of efalizumabwithdrawal flare and psoriasis-precipitated depression. Australas. J.Dermatol., 2008, 49(4), 250-251. http://dx.doi.org/10.1111/j.1440-0960.2008.00487.x
125. Tookman, A.J.; Jones, C.L.; DeWitte, M.; Lodge, P.J. Fatigue inpatients with advanced cancer: a pilot study of an intervention withinfliximab. Support. Care Cancer, 2008, 16(10), 1131-1140. http://dx.doi.org/10.1007/s00520-008-0429-x
126. Mehta, D.; Raison, C.L.; Woolwine, B.J. Transcriptional signaturesrelated to glucose and lipid metabolism predict treatment responseto the tumor necrosis factor antagonist infliximab in patients withtreatment-resistant depression. Brain Behav. Immun., 2013, 31,205-215. http://dx.doi.org/10.1016/j.bbi.2013.04.004
127. Cattaneo, A.; Gennarelli, M.; Uher, R. Candidate genes expressionprofile associated with antidepressants response in the GENDEPstudy: differentiating between baseline 'predictors' and longitudinal'targets'. Neuropsychopharmacology, 2013, 38(3), 377-385. http://dx.doi.org/10.1038/npp.2012.191
128. Powell, T.R.; Schalkwyk, L.C.; Heffernan, A.L. Tumor necrosisfactor and its targets in the inflammatory cytokine pathway areidentified as putative transcriptomic biomarkers for escitalopramresponse. Eur. Neuropsychopharmacol., 2013, 23(9), 1105-1114. http://dx.doi.org/10.1016/j.euroneuro.2012.09.009
129. Kekow, J.; Moots, R.; Khandker, R.; Melin, J.; Freundlich, B.; Singh, A. Improvements in patient-reported outcomes, symptomsof depression and anxiety, and their association with clinicalremission among patients with moderate-to-severe active earlyrheumatoid arthritis. Rheumatology (Oxford), 2011, 50(2), 401-409. http://dx.doi.org/10.1093/rheumatology/keq327
130. Machado, D.A.; Guzman, R.M.; Xavier, R.M. Open-labelobservation of addition of etanercept versus a conventional diseasemodifyingantirheumatic drug in subjects with active rheumatoidarthritis despite methotrexate therapy in the Latin American region. J. Clin. Rheumatol., 2014, 20(1), 25-33. http://dx.doi.org/10.1097/RHU.0000000000000055
131. Gelfand, J.M.; Kimball, A.B.; Mostow, E.N. Patient-reportedoutcomes and health-care resource utilization in patients withpsoriasis treated with etanercept: continuous versus interruptedtreatment. Value Health, 2008, 11(3), 400-407. http://dx.doi.org/10.1111/j.1524-4733.2007.00251.x
132. Dauden, E.; Griffiths, C.E.; Ortonne, J. P. Improvements in patientreportedoutcomes in moderate-to-severe psoriasis patientsreceiving continuous or paused etanercept treatment over 54 weeks:the CRYSTEL study. J. Eur. Acad. Dermatol. Venereol., 2009, 23(12), 1374-1382. http://dx.doi.org/10.1111/j.1468-3083.2009.03321.x
133. Tyring, S.; Gottlieb, A.; Papp, K. Etanercept and clinical outcomes,fatigue, and depression in psoriasis: double-blind placebocontrolledrandomised phase III trial. Lancet, 2006, 367(9504), 29-35. http://dx.doi.org/10.1016/S0140-6736(05)67763-X
134. Krishnan, R.; Cella, D.; Leonardi, C. Effects of etanercept therapyon fatigue and symptoms of depression in subjects treated formoderate to severe plaque psoriasis for up to 96 weeks. Br. J.Dermatol., 2007, 157(6), 1275-1277. http://dx.doi.org/10.1111/j.1365-2133.2007.08205.x
135. Gniadecki, R.; Robertson, D.; Molta, C.T. Self-reported healthoutcomes in patients with psoriasis and psoriatic arthritisrandomized to two etanercept regimens. J. Eur. Acad. Dermatol.Venereol., 2012, 26(11), 1436-1443. http://dx.doi.org/10.1111/j.1468-3083.2011.04308.x
136. Papp, K.; Poulin, Y.; Vieira, A.; Shelton, J.; Poulin-Costello, M. Disease characteristics in patients with and without psoriaticarthritis treated with etanercept. J. Eur. Acad. Dermatol. Venereol.,2014, 28(5), 581-589. http://dx.doi.org/10.1111/jdv.12138
137. Loftus, E.V.; Feagan, B.G.; Colombel, J.F. Effects of adalimumabmaintenance therapy on health-related quality of life of patientswith Crohn's disease: patient-reported outcomes of the CHARMtrial. Am. J. Gastroenterol., 2008, 103(12), 3132-3141. http://dx.doi.org/10.1111/j.1572-0241.2008.02175.x
138. Menter, A.; Augustin, M.; Signorovitch, J. The effect of adalimumabon reducing depression symptoms in patients with moderate tosevere psoriasis: A randomized clinical trial. J. Am. Acad. Dermatol.,2010, 62(5), 812-818. http://dx.doi.org/10.1016/j.jaad.2009.07.022
139. Arisoy, O.; Bes, C.; Cifci, C.; Sercan, M.; Soy, M. The effect ofTNF-alpha blockers on psychometric measures in ankylosingspondylitis patients: a preliminary observation. Rheumatol. Int.,2013, 33(7), 1855-1864. http://dx.doi.org/10.1007/s00296-013-2671-x
140. Tong, Q.; Zhao, L.; Qian, X.D. Association of TNF-alphapolymorphism with prediction of response to TNF blockers inspondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenom. J, 2013, 14(14), 1691-1700. http://dx.doi.org/10.2217/pgs.13.146
141. Lee, Y.H.; Ji, J.D.; Bae, S.C.; Song, G.G. Associations betweentumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/Apolymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.J. Rheumatol., 2010, 37(4), 740-746. http://dx.doi.org/10.3899/jrheum.090707
142. Morales-Lara, M.J.; Canete, J.D.; Torres-Moreno, D. Effects ofpolymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine, 2012, 79(6), 591-596. http://dx.doi.org/10.1016/j.jbspin.2012.02.003
143. Prajapati, R.; Plant, D.; Barton, A. Genetic and genomic predictors ofanti-TNF response. Pharmacogenom. J., 2011, 12(11), 1571-1585. http://dx.doi.org/10.2217/pgs.11.114
144. Uguz, F.; Akman, C.; Kucuksarac, S.; Tufekci, O. Anti-tumornecrosis factor-alpha therapy is associated with less frequent moodand anxiety disorders in patients with rheumatoid arthritis. PsychiatryClin. Neurosci., 2009, 63(1), 50-55. http://dx.doi.org/10.1111/j.1440-1819.2008.01905.x
145. Insel, T.R.; Voon, V.; Nye, J.S. Innovative solutions to novel drugdevelopment in mental health. Neurosci. Biobehav. Rev., 2013,37(Pt 1), 2438-2444. http://dx.doi.org/10.1016/j.neubiorev.2013.03.022
146. Raftery, G.; He, J.; Pearce, R. Disease activity and cognition inrheumatoid arthritis: an open label pilot study. Arthritis Res. Ther.,2012, 14(6), R263. http://dx.doi.org/10.1186/ar4108
147. Elfferich, M.D.; Nelemans, P.J.; Ponds, R.W.; De Vries, J.; Wijnen, P.A.; Drent, M. Everyday cognitive failure in sarcoidosis:the prevalence and the effect of anti-TNF-alpha treatment. Respiration, 2010, 80(3), 212-219. http://dx.doi.org/10.1159/000314225
148. Tobinick, E.L.; Gross, H. Rapid improvement in verbal fluency andaphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol., 2008, 8, 27. http://dx.doi.org/10.1186/1471-2377-8-27
149. Thalayasingam, N.; Isaacs, J.D. Anti-TNF therapy. Best Pract. Res.Clin. Rheumatol., 2011, 25 (4), 549-567. http://dx.doi.org/10.1016/j.berh.2011.10.004
150. Insel, T.R. The NIMH Research Domain Criteria (RDoC) Project:precision medicine for psychiatry. Am. J. Psychiatry, 2014, 171(4),395-397. http://dx.doi.org/10.1176/appi.ajp.2014.14020138